Physician profile
Christopher J Achee
NPI 1710947205
$3,764.16
in general payments reported to CMS, 2019-2025
29 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $92.12 · 2021: $504 · 2022: $722 · 2023: $868 · 2024: $509 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $990.60 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $607.01 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $295.23 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.56 | 2019-2023 | Jardiance |
| Ardelyx, INC. | $206.53 | 2023-2025 | Ibsrela |
| Amgen INC. | $142.21 | 2019-2022 | |
| Novo Nordisk INC | $139.46 | 2019-2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $130.99 | 2019-2025 | Vaxelis, Rotateq, Capvaxive |
| Novartis Pharmaceuticals Corporation | $103.49 | 2022-2024 | |
| Pfizer INC. | $96.81 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.04 | 2023-2025 | Caplyta |
| Intuitive Surgical, INC. | $90.90 | 2023 | Da Vinci Surgical System |
| Astellas Pharma US INC | $69.50 | 2019-2023 | Veozah, Myrbetriq |
| Alkermes, INC. | $67.40 | 2022-2023 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $62.76 | 2019-2024 | Arexvy, Shingrix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $58.73 | 2021-2023 | Trintellix |
| Exact Sciences Corporation | $54.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $40.60 | 2022 | |
| Indivior INC. | $37.08 | 2025 | Sublocade |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.05 | 2022 | |
| Axsome Therapeutics, INC. | $30.00 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $25.17 | 2019 | |
| Allergan, INC. | $23.63 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.22 | 2024 | |
| Supernus Pharmaceuticals, INC. | $14.32 | 2024 | Qelbree |
| Sanofi Pasteur INC. | $13.97 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.10 | 2023 | Abilify Maintena, Rexulti |
| Biofire Diagnostics, LLC | $13.04 | 2021 | |
| Biomerieux INC | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Achee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.